Introduction: Infections caused by Candida auris, an emerging multidrug-resistant yeast, are considered a public health problem due to its potential to cause invasive infections, with isolation being associated with high mortality rates. This study aims to describe and characterize the sociodemographic features of patients with C. auris isolation in a tertiary care institution, generating evidence that can be utilized to expand understanding of its outcomes, patterns of antifungal resistance, and treatment strategies. Methodology: This study is a description of patients with Candida auris isolation, a case series conducted retrospectively, treated at the Fundación Cardioinfantil – Instituto de Cardiología in Bogotá from 2018 to 2023. Results: A total of 9 patients were included, all of whom were male, with a mean age of 52 years. Common comorbidities included: 44.4% had a history of hypertension, 44.4% had COVID-19 infection, and 33% had cardiac disease. The ICU was where most cases were isolated (66.6%). The most frequent clinical presentation was fungemia (66.6%), with no isolates obtained other than those from blood or urine cultures. 66.6% of patients received antifungal treatment, with caspofungin being the most commonly prescribed, and the mortality rate among treated patients was 16%. Conclusions: Despite the study's limitations, rapid identification of the microorganism using molecular methods (in this case, PCR) and early treatment with effective therapy (caspofungin) were associated with improved survival, establishing it as an excellent first-line therapy for invasive C. auris infections. Additionally, proper implementation of infection prevention and control measures has led to few isolates of this multidrug-resistant yeast in the institution, thus, its acceptance and usage should be encouraged.
